A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies This is a multicenter, non-randomized open-label, Phase 2 dose escalation and confirmation followed by a multi-cohort single-group study. This study is designed to first establish the RP2D and then as a proof-of-concept to assess the efficacy and safety of MK-1026
monotherapy across cohorts of participants with various hematological malignancies who
have relapsed or are refractory to prior therapies. BTK inhibitors are approved for the
treatment of several lymphoproliferative malignancies; however, resistance is known to
develop. These hematologic malignancies were selected because each represents a significant
unmet medical need and prior BTK inhibitors have shown efficacy in these malignancies.
A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies This is a multicenter, non-randomized open-label, Phase 2 dose escalation and confirmation followed by a multi-cohort single-group study. This study is designed to first establish the RP2D and then as a proof-of-concept to assess the efficacy and safety of MK-1026
monotherapy across cohorts of participants with various hematological malignancies who
have relapsed or are refractory to prior therapies. BTK inhibitors are approved for the
treatment of several lymphoproliferative malignancies; however, resistance is known to
develop. These hematologic malignancies were selected because each represents a significant
unmet medical need and prior BTK inhibitors have shown efficacy in these malignancies.
